Quick answers
- What is Fedratinib hydrochloride used for?
- The FDA-approved label (Inrebic, Celgene Corporation, July 20, 2026) says: “INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Fedratinib hydrochloride have a boxed warning?
- Yes. The FDA label for Inrebic has a boxed warning (“WARNING: ENCEPHALOPATHY INCLUDING WERNICKE'S”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Fedratinib hydrochloride?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Fedratinib hydrochloride been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Fedratinib hydrochloride?
- 1 company lists prescription products of Fedratinib hydrochloride in the FDA NDC Directory, including Celgene Corporation.
What Fedratinib hydrochloride is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
— FDA label: Inrebic, Celgene Corporation, effective July 20, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: ENCEPHALOPATHY INCLUDING WERNICKE'S
. Read it on the full label →
Forms and how it is given
| Dosage forms | Capsule |
|---|---|
| Route | Oral |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Inrebic |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Celgene Corporation1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA212327 INREBIC | Bristol-Myers | August 16, 2019 | 7, latest July 20, 2026 2026: Labeling · 2026: Labeling · 2025: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2197495, 2197501 |
|---|---|
| SPL set ID of the quoted label | f0f55a2a-4e0c-4cba-8571-03e1424486d7 |
| FDA labels (SPL) | 1 |
| FDA applications | NDA212327 |
| Active ingredients (FDA) | FEDRATINIB |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Inrebic, Celgene Corporation, effective July 20, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →